![](https://news.europawire.eu/wp-content/uploads/2020/09/Libtayo-positive-pivotal-data-presented-at-ESMO-Virtual-Congress-2020-144x144.png)
Libtayo is the first investigational medicine to show a clinical benefit in advanced basal cell carcinoma following treatment with a hedgehog inhibitor in a prospective trial 31% objective response rate seen in trial patients, and an estimated 85% of responses … Read the full press release